WASHINGTON (Reuters) - U.S. Senate Democrats said they plan to slow Senate business to a crawl starting Monday evening to protest behind-the-scenes Republican work on repealing former President Barack Obama's healthcare law, known as Obamacare.
(Reuters) - Seattle Genetics Inc said it would halt a late-stage study of its drug to treat a type of leukemia in older patients following a "higher rate" of deaths in patients on the drug compared with those on a placebo.
LONDON (Reuters) - GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.
LONDON (Reuters) - Scientists said on Monday they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.
(Reuters) - Positive late-stage data on Clovis Oncology Inc's ovarian cancer drug, Rubraca, could help widen the use of the therapy and differentiate it from rivals, the U.S. biotech said on Monday, sending its shares soaring 48 percent.
NEW DELHI (Reuters) - A group of U.S. lawmakers has backed medical device makers by urging India to reconsider its decision to cap prices of heart stents, raising the issue ahead of Prime Minister Narendra Modi's visit to the United States later this week.
TEL AVIV (Reuters) - Israel's Gamida Cell, which is developing cellular therapies to treat cancer and rare genetic diseases, said on Monday it raised $40 million to finance the advanced trial of its product NiCord to facilitate bone marrow transplants.
ZURICH (Reuters) - Swiss drugmaker Novartis on Monday said it had won European approval for its biosimilar version of Roche's blockbuster Rituxan as the crosstown rivals go head-to-head on a drug to treat blood cancers and immunological diseases.
WASHINGTON (Reuters) - California on Monday will announce plans to award $20 million in emergency grants to local health and Planned Parenthood clinics in anticipation of possible U.S. healthcare funding cuts, according to State Treasurer John Chiang's office.
(Reuters Health) - - Death rates from liver cancer in the U.S. have doubled since the 1980s and continue to rise, largely due to risk factors like hepatitis that should be the focus of better treatment and prevention efforts, researchers say.